An Overview of the Diagnosis and Management of Seborrheic Dermatitis
Federica Dall'Oglio,Maria Rita Nasca,Carlo Gerbino,Giuseppe Micali
DOI: https://doi.org/10.2147/CCID.S284671
2022-08-06
Abstract:Federica Dall'Oglio, Maria Rita Nasca, Carlo Gerbino, Giuseppe Micali Dermatology Clinic, University of Catania, Catania, Italy Correspondence: Giuseppe Micali, Dermatology Clinic, University of Catania, Via S. Sofia 78, Catania, 95123, Italy, Tel + 39 095 321705, Fax + 39 095 3782425, Email Seborrheic dermatitis (SD) is a common chronic inflammatory skin disorder that mostly affects young adults in areas rich in sebaceous glands (scalp, face, and trunk). In adolescents and adults, SD clinical presentation may range from mild patches to diffuse scalp scaling. In infants, it mainly occurs on the scalp as yellowish, scaly patches ("cradle cap"). In adults, several environmental triggers are likely to promote SD development, along with fungal colonization by Malassezia spp., sebaceous gland activity, as well as immunosuppression, endocrine, neurogenic and iatrogenic factors. In children, early occurrence in the first trimester suggests the role of excessive sebaceous gland activity from maternal hormones, along with cutaneous microbiome alterations. The diagnosis of SD is usually clinical, and specific laboratory and/or instrumental investigations are seldom required. Treatment is aimed at modulating sebum production, reducing skin colonization by Malassezia spp., and controlling inflammation. In adults, mild-to-moderate scalp SD forms can be managed with topical antifungals (ketoconazole, ciclopirox, miconazole) or antiinflammatory (mild-to-moderate potency corticosteroids) or keratolytic/humectant (propylene glycol) agents. Recommended topical therapeutic options for mild-to-moderate facial or body areas SD include topical ketoconazole, ciclopirox, clotrimazole, mild-to-moderate potency corticosteroids, lithium succinate/gluconate, and topical calcineurin inihibitors ( off-label use ). In severe and/or resistant cases, the use of systemic antifungal drugs (terbinafine, itraconazole), as well as UVB phototherapy, may be considered. In children, scant scientific evidence supports the effectiveness and safety of topical drugs, and "cradle cap" is usually successfully managed with baby shampoos enriched with emollient agents and vegetable oils. Alternatively, similarly to adult scalp SD, medical device shampoos with antiinflammatory and antifungal properties, containing piroctone olamine, bisabolol, alyglicera, telmesteine, may be used. Beyond pharmacological treatments, an appropriate cosmetic approach, if correctly prescribed, may improve therapeutic outcomes. Keywords: seborrheic dermatitis, diagnosis, therapy, topical, systemic, cosmetics Seborrheic dermatitis (SD) is a common chronic inflammatory skin disorder that most commonly affects young adults, and less often children. In adolescents and adults, SD clinical presentation may range from a mild scalp scaling to diffuse white, yellowish patches in regions rich in sebaceous glands such as scalp, face and trunk. 1,2 In infants, SD mainly occurs on the scalp as yellowish, scaly patches, with varying degrees of inflammation, configuring the so-called "cradle cap". 2,3 SD pathogenesis is multifactorial and still poorly delineated. Although some environmental triggers (eg, low temperature and humidity in winter) are likely to promote its development, several other factors, including fungal colonization by Malassezia spp. (formerly called Pityrosporum ovale ), sebaceous gland activity, as well as immunosuppression, endocrine, neurogenic and iatrogenic factors, have been postulated. 3–6 In children, common early occurrence in the first trimester suggests the role of excessive sebaceous gland activity from maternal hormones, along with cutaneous microbiome alterations, including Malassezia spp., Staphylococcus spp., Streptococcus spp., and Corynebacterium spp. 7 The diagnosis of SD is usually easy and based on clinical observation, and specific investigations are rarely required. Treatment of SD is aimed at modulating sebum production, reducing skin colonization by Malassezia spp., and controlling inflammation. In mild-to-moderate SD forms, topical treatments represent the primary therapeutic approach; in severe and/or resistant cases the off-label use of some topical and systemic drugs, as well as physical treatment with UVB phototherapy, may be considered. The aim of our study is to provide an updated review on diagnostic investigations and therapeutic management of SD in immunocompetent subjects (adults or children) and in some conditions in which a high prevalence of SD is observed, such as HIV/AIDS, neurologic disorders, Parkinson's disease, facial paralysis and Down's syndrome. In addition, some drugs considered as possible contributing SD-like dermatitis factors are also considered. We performed a revision of the literature -Abstract Truncated-